Dr. Ou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 South Manchester Ave, Suite 400
Orange, CA 92868Phone+1 714-456-5153- Is this information wrong?
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
- Duke University HospitalResidency, Internal Medicine, 1997 - 2000
- University of Texas Southwestern Medical SchoolClass of 1997
Certifications & Licensure
- NC State Medical License 1999 - 2025
- AZ State Medical License 2008 - 2025
- CA State Medical License 2003 - 2025
- TX State Medical License 2010 - 2024
- MA State Medical License 2000 - 2017
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities Start of enrollment: 2020 Dec 16
Roles: Contact
Publications & Presentations
PubMed
- A pragmatic guide for management of adverse events associated with lorlatinib.Geoffrey Liu, Julien Mazieres, Jan Stratmann, Tony Mok, Mary Grizzard, Yasushi Goto, Enriqueta Felip, Benjamin J Solomon, Sai-Hong Ignatius Ou, Todd M Bauer> ;Lung Cancer. 2024 May 1
- Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.Lanyi Nora Chen, Alexandria T M Lee, Misako Nagasaka, Sai-Hong Ignatius Ou> ;Journal of Thoracic Oncology. 2024 Mar 1
- MARIPOSA-2: Is the treatment worse than the disease?Lee, A., Ou, S.> ;Med. 2024 Feb 9
- Join now to see all
Lectures
- Liquid Biopsy to Identify Actionable Genomic Alterations2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
- Medical Oncologist’s Perspective2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Join now to see all
Hospital Affiliations
- UCI HealthOrange, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: